Category Archives: AZBio News

Eye Test Identifies Alzheimer’s

Posted on by

(BUSINESS WIRE)–Nov 15, 2013–Cognoptix disclosed today at the ‘Clinical Trials on Alzheimer’s Disease’ (CTAD) scientific meeting the strong results of a multi-site clinical trial of its SAPPHIRE II eye test, which is designed to identify Alzheimer’s Disease (AD) patients via a beta-amyloid (Ab) signature in their eyes.Continue reading→

FTC Seeking Public Comment on Follow-On Biologics

Posted on by

The Federal Trade Commission (FTC) is seeking public comment on follow-on biologics.

In addition, the FTC will hold a public workshop on December 1oth.

The Follow-On Biologics Workshop: Impact of Recent Legislative and Regulatory Naming Proposals on Competition

The  Federal Trade Commission announces it will hold a workshop to explore  competition issues involving biologic medicines and follow-on biologics. As  described in the Federal Register Notice, the workshop will focus on a few key  issues, inter alia:

  • The potential impact of state regulations affecting competition.
  • How regulations, if necessary, might be structured to facilitate competition  while still protecting patient health and safety.
  •   How naming may affect competition.
  • The experience of other countries with follow-on biologic competition.

The  Federal Register Notice poses a series of questions about which the FTC seeks  public comment. The FTC will take these comments into account in its  examination of these topics.

Previous Biologics Workshops and Report:

Event Details

WHEN:

December 10, 2013 Time: 9am – 5pm

WHERE:

FTC Conference Center

601 New Jersey Avenue, NW

Washington, DC

Learn more at http://www.ftc.gov/opp/workshops/biologics/#nj

Amgen To Webcast Investor Meeting At Upcoming American Heart Association Scientific Sessions 2013

Posted on by
THOUSAND OAKS, Calif., Nov. 14, 2013 /PRNewswire via COMTEX/ — Amgen (AMGN) will host a webcast investor meeting at the American Heart Association (AHA) Scientific Sessions 2013 on Tuesday, Nov. 19, at 7 p.m. CST. Sean E. Harper, M.D., executive vice president of Research and Development at Amgen, along with members of Amgen’s clinical development team and clinical investigators, will participate at the investor meeting to discuss data being presented at AHA.Continue reading→

SGB and Yulex Partner to Double Guayule Rubber Yield Through an Accelerated Breeding Platform

Posted on by

SAN DIEGO, CA and PHOENIX, AZ–(Marketwired – Nov 12, 2013) –  SGB Inc., an agricultural biotechnology company, and Yulex  Corporation, a biomaterial company, announced today a collaboration to establish  a genomics and molecular breeding platform focused on accelerating the crop  improvement of Guayule as a sustainable source of biorubber that can replace  traditional tropical or petroleum-based rubber for medical, consumer and  industrial markets.Continue reading→